公开(公告)号：US11850288B2

公开(公告)日：2023-12-26

申请号：US16916836

申请日：2020-06-30

申请人： CURAMYS INC.

发明人： Jung-Joon Sung ,  Seung-Yong Seong ,  Hee-Woo Lee ,  Ki Yoon Kim

IPC分类号： A61K48/00 ,  C07K14/005 ,  A61K35/545 ,  C12N5/0775 ,  C12N5/12 ,  C12N5/0793 ,  C12N15/85 ,  A61P21/00 ,  A61P25/00 ,  A61K35/30 ,  C12N5/0735 ,  C12N5/074 ,  C12N5/16 ,  C12N9/24 ,  A61K38/00

CPC分类号： A61K48/005 ,  A61K35/30 ,  A61K35/545 ,  A61P21/00 ,  A61P25/00 ,  C07K14/005 ,  C12N5/0606 ,  C12N5/0619 ,  C12N5/0667 ,  C12N5/0696 ,  C12N5/12 ,  C12N5/16 ,  C12N9/2402 ,  C12N15/85 ,  A61K38/00 ,  C12N2760/18822 ,  C12N2760/18833

摘要： A gene and cell therapy using a cell fusion technology is proposed. Cells overexpressing hemagglutinin neuraminidase (HN) and fusion (F) proteins have effects of enhancing cell fusion with other cells, restoring cell damage through the cell fusion with damaged cells, and transferring a normal gene. Therefore, when a vector including genes encoding the HN and F proteins of the present invention or a cell transformed with the vector is clinically applied to neurodegenerative diseases, muscular diseases, and the like, an effect of reducing the damage of damaged cells through cell fusion can be expected.

公开(公告)号：US09821016B2

公开(公告)日：2017-11-21

申请号：US13656913

申请日：2012-10-22

申请人： Eberhard-Karls-Universitaet Tuebingen Universitaetsklinikum

发明人： Ulrich Manfred Lauer ,  Michael Bitzer ,  Martina Zimmermann ,  Sorin Armeanu-Ebinger ,  Sascha Bossow ,  Wolfgang Neubert

IPC分类号： A61K48/00 ,  C07H21/04 ,  A61K35/76 ,  C07K14/005 ,  A61K35/768 ,  A01K67/00 ,  A61K39/00

CPC分类号： A61K35/76 ,  A61K35/768 ,  A61K2039/5256 ,  C07K14/005 ,  C12N2760/18822 ,  C12N2760/18832

摘要： The present invention relates to a genetically modified Paramyxovirus, a pharmaceutical composition comprising this paramyxovirus, the use of a genetically modified Paramyxovirus for the therapeutic and/or prophylactic treatment of a tumor disease, and a method for the production of a pharmaceutical composition for the therapeutic or prophylactic treatment of a tumor disease.

公开(公告)号：US20100323428A1

公开(公告)日：2010-12-23

申请号：US12526211

申请日：2008-02-07

申请人： Mariko Yoshizaki ,  Makota Inoue ,  Mamoru Hasegawa

发明人： Mariko Yoshizaki ,  Makota Inoue ,  Mamoru Hasegawa

IPC分类号： C12N7/01 ,  C12N15/63

CPC分类号： C12N7/00 ,  A61K48/00 ,  A61K2039/5254 ,  C07K14/005 ,  C12N2760/18822 ,  C12N2760/18861

摘要： An objective of the present invention is to provide attenuated minus-strand RNA viruses. The present inventors discovered that the amino acid mutation at position 1214 (Y1214F) in the amino acid sequence of L protein of Sendai virus suppressed the viral genome replication activity and/or transcription activity. The inventors also found that the deletion of a particular gene from the viral genome could result in much less cytotoxicity and immune response than conventional. The inventors thus completed the present invention.

摘要翻译： 本发明的目的是提供减毒的负链RNA病毒。 本发明人发现仙台病毒L蛋白的氨基酸序列中第1214位氨基酸突变（Y1214F）抑制病毒基因组复制活性和/或转录活性。 本发明人还发现，从病毒基因组中删除特定基因可导致远低于常规的细胞毒性和免疫应答。 本发明人完成了本发明。

公开(公告)号：US20080227740A1

公开(公告)日：2008-09-18

申请号：US11932400

申请日：2007-10-31

申请人： Stephen James Russell ,  Frances Joanne Morling ,  Adele Kay Fielding ,  Francois-Loic Cosset ,  Roberto Cattaneo

发明人： Stephen James Russell ,  Frances Joanne Morling ,  Adele Kay Fielding ,  Francois-Loic Cosset ,  Roberto Cattaneo

IPC分类号： A61K31/70

CPC分类号： C07K14/005 ,  A61K38/162 ,  A61K48/00 ,  C07K2319/00 ,  C07K2319/50 ,  C12N15/86 ,  C12N2710/16622 ,  C12N2710/16722 ,  C12N2710/24022 ,  C12N2740/13022 ,  C12N2740/13043 ,  C12N2740/13045 ,  C12N2760/18422 ,  C12N2760/18622 ,  C12N2760/18722 ,  C12N2760/18822 ,  C12N2810/851 ,  C12N2840/203

摘要： Disclosed are compositions comprising a recombinant nucleic acid vector including a nucleotide sequence encoding a syncytium-inducing polypeptide expressible on a eukaryotic cell surface, and a host cell containing the recombinant vector and expressing the syncytium inducing polypeptide on its cell surface, the vectors and resultant host cells expressing the syncytium inducing polypeptide being useful for selective elimination of unwanted cells.

公开(公告)号：US20050152916A1

公开(公告)日：2005-07-14

申请号：US11005750

申请日：2004-12-07

申请人： Zeling Cai ,  Jonathan Sprent ,  Anders Brunmark ,  Michael Jackson ,  Per Peterson ,  Alain Luxembourg ,  Didier Leturcq ,  Ann Moriarty

发明人： Zeling Cai ,  Jonathan Sprent ,  Anders Brunmark ,  Michael Jackson ,  Per Peterson ,  Alain Luxembourg ,  Didier Leturcq ,  Ann Moriarty

IPC分类号： C12N15/09 ,  A61K35/14 ,  A61K38/00 ,  A61K39/00 ,  A61K48/00 ,  A61P35/00 ,  C07K14/025 ,  C07K14/145 ,  C07K14/705 ,  C07K14/74 ,  C12N5/07 ,  C12N5/0783 ,  C12N5/10 ,  C12N15/12 ,  C12N15/85 ,  C12P21/02

CPC分类号： C12N5/0601 ,  A61K38/00 ,  A61K2039/5158 ,  C07K14/005 ,  C07K14/70503 ,  C07K14/70539 ,  C12N5/0636 ,  C12N15/85 ,  C12N2501/50 ,  C12N2501/51 ,  C12N2502/50 ,  C12N2502/99 ,  C12N2760/16122 ,  C12N2760/18822 ,  C12N2760/20222 ,  C12N2830/002 ,  C12N2830/75 ,  C12N2830/80 ,  Y10S530/812 ,  Y10S530/827

摘要： The present invention relates to synthetic antigen-presenting matrices, their methods of making and their methods of use. One such matrix is cells that have been transfected to produce MHC antigen-presenting molecules and assisting molecules such as co-stimulatory molecules. The matrices can be used to activate CD8+ T-cells to produce cytokines and become cytotoxic.

摘要翻译： 本发明涉及合成抗原呈递矩阵，其制备方法及其使用方法。 一种这样的基质是已被转染以产生MHC抗原呈递分子并辅助分子如共刺激分子的细胞。 该基质可用于激活CD8 + T细胞以产生细胞因子并变成细胞毒性。

公开(公告)号：US06723532B2

公开(公告)日：2004-04-20

申请号：US09070938

申请日：1998-04-30

申请人： Yoshiyuki Nagai ,  Atsushi Kato ,  Fukashi Murai ,  Makoto Asakawa ,  Tsuneaki Sakata ,  Mamoru Hasegawa ,  Tatsuo Shioda

发明人： Yoshiyuki Nagai ,  Atsushi Kato ,  Fukashi Murai ,  Makoto Asakawa ,  Tsuneaki Sakata ,  Mamoru Hasegawa ,  Tatsuo Shioda

IPC分类号： C12N1500

CPC分类号： C12N15/86 ,  C07K14/005 ,  C12N7/00 ,  C12N2740/16122 ,  C12N2760/18821 ,  C12N2760/18822 ,  C12N2760/18843 ,  C12N2760/18852

摘要： A method for reconstituting Sendai viral particles by transfecting Sendai virus to a host expressing all genes for the initial replication has been developed, enabling the Production of negative strand RNA vectors highly useful for practical applications.

摘要翻译： 已经开发了通过将仙台病毒转染到表达用于初始复制的所有基因的宿主来重建仙台病毒颗粒的方法，使得能够生产对实际应用非常有用的负链RNA载体。

公开(公告)号：US20030077708A1

公开(公告)日：2003-04-24

申请号：US10105678

申请日：2002-03-25

申请人： The Scripps Research Institute

发明人： Zeling Cai ,  Jonathan Sprent ,  Anders Brunmark ,  Michael Jackson ,  Per A. Peterson

IPC分类号： A61K048/00 ,  C12P021/02 ,  C12N005/06 ,  C07K014/74

CPC分类号： C12N5/0601 ,  A61K38/00 ,  A61K2039/5158 ,  C07K14/005 ,  C07K14/70503 ,  C07K14/70539 ,  C12N5/0636 ,  C12N15/85 ,  C12N2501/50 ,  C12N2501/51 ,  C12N2502/50 ,  C12N2502/99 ,  C12N2760/16122 ,  C12N2760/18822 ,  C12N2760/20222 ,  C12N2830/002 ,  C12N2830/75 ,  C12N2830/80 ,  Y10S530/812 ,  Y10S530/827

摘要： Materials and methods for activating T lymphocytes with specificity for particular antigenic peptides are described, as well as the use of activated T lymphocytes in vitro for the treatment of a variety of disease conditions. In particular, a method for producing a synthetic antigen presenting cell line for activating T lymphocytes to a specific peptide is described.

摘要翻译： 描述了用于特异性激活特定抗原肽的T淋巴细胞的材料和方法，以及活体T淋巴细胞在体外用于治疗各种疾病状况的用途。 特别地，描述了一种用于产生用于将T淋巴细胞活化到特定肽的合成抗原呈递细胞系的方法。

公开(公告)号：US20030077318A1

公开(公告)日：2003-04-24

申请号：US10105504

申请日：2002-03-25

申请人： The Scripps Research Institute

发明人： Zeling Cai ,  Jonathan Sprent ,  Anders Brunmark ,  Michael Jackson ,  Per A. Peterson

IPC分类号： A61K009/127 ,  A61K038/17 ,  C07K014/74

CPC分类号： C12N5/0601 ,  A61K38/00 ,  A61K2039/5158 ,  C07K14/005 ,  C07K14/70503 ,  C07K14/70539 ,  C12N5/0636 ,  C12N15/85 ,  C12N2501/50 ,  C12N2501/51 ,  C12N2502/50 ,  C12N2502/99 ,  C12N2760/16122 ,  C12N2760/18822 ,  C12N2760/20222 ,  C12N2830/002 ,  C12N2830/75 ,  C12N2830/80 ,  Y10S530/812 ,  Y10S530/827

摘要： Materials and methods for activating T lymphocytes with specificity for particular antigenic peptides are described, as well as the use of activated T lymphocytes in vitro for the treatment of a variety of disease conditions. In particular, a method for producing a synthetic antigen presenting cell line for activating T lymphocytes to a specific peptide is described.

摘要翻译： 描述了用于特异性激活特定抗原肽的T淋巴细胞的材料和方法，以及活体T淋巴细胞在体外用于治疗各种疾病状况的用途。 特别地，描述了一种用于产生用于将T淋巴细胞活化到特定肽的合成抗原呈递细胞系的方法。

公开(公告)号：US20030072796A1

公开(公告)日：2003-04-17

申请号：US10105200

申请日：2002-03-25

申请人： The Scripps Research Institute

发明人： Zeling Cai ,  Jonathan Sprent ,  Anders Brunmark ,  Michael Jackson ,  Per A. Peterson

IPC分类号： A61K009/127 ,  A61K038/17 ,  C07K014/74

CPC分类号： C12N5/0601 ,  A61K38/00 ,  A61K2039/5158 ,  C07K14/005 ,  C07K14/70503 ,  C07K14/70539 ,  C12N5/0636 ,  C12N15/85 ,  C12N2501/50 ,  C12N2501/51 ,  C12N2502/50 ,  C12N2502/99 ,  C12N2760/16122 ,  C12N2760/18822 ,  C12N2760/20222 ,  C12N2830/002 ,  C12N2830/75 ,  C12N2830/80 ,  Y10S530/812 ,  Y10S530/827

摘要： Materials and methods for activating T lymphocytes with specificity for particular antigenic peptides are described, as well as the use of activated T lymphocytes in vitro for the treatment of a variety of disease conditions. In particular, a method for producing a synthetic antigen presenting cell line for activating T lymphocytes to a specific peptide is described.

摘要翻译： 描述了用于特异性激活特定抗原肽的T淋巴细胞的材料和方法，以及活体T淋巴细胞在体外用于治疗各种疾病状况的用途。 特别地，描述了一种用于产生用于将T淋巴细胞活化到特定肽的合成抗原呈递细胞系的方法。

公开(公告)号：US20180193487A1

公开(公告)日：2018-07-12

申请号：US15873488

申请日：2018-01-17

申请人： SEOUL NATIONAL UNIVERSITY HOSPITAL

发明人： Jung-Joon SUNG ,  Seung-Yong SEONG ,  Hee-Woo LEE ,  Ki Yoon Kim

IPC分类号： A61K48/00 ,  A61K35/30 ,  C12N9/24 ,  C12N5/0735 ,  C12N5/074 ,  C12N5/16 ,  A61P25/00 ,  A61P21/00

CPC分类号： A61K48/005 ,  A61K35/30 ,  A61K35/545 ,  A61K38/00 ,  A61P21/00 ,  A61P25/00 ,  C07K14/005 ,  C12N5/0606 ,  C12N5/0619 ,  C12N5/0667 ,  C12N5/0696 ,  C12N5/12 ,  C12N5/16 ,  C12N9/2402 ,  C12N2760/18822 ,  C12N2760/18833

摘要： The present invention relates to gene and cell therapy using a cell fusion technology and more particularly, cells overexpressing hemagglutinin neuraminidase (HN) and fusion (F) proteins have effects of enhancing cell fusion with other cells, restoring cell damage through the cell fusion with damaged cells, and transferring a normal gene. Therefore, when a vector including genes encoding the HN and F proteins of the present invention or a cell transformed with the vector is clinically applied to neurodegenerative diseases, muscular diseases, and the like, an effect of reducing the damage of damaged cells through cell fusion can be expected.